×
About 275,700 results

Benefits of Post-Op Penile Traction Therapy Hold Up Over Time
https://www.medpagetoday.com/urology/prostatecancer/95226

Oct 23rd, 2021 - SCOTTSDALE, Ariz. -- A penile traction therapy (PTT) device produced lasting improvements in men after prostatectomy, a researcher reported. The current data builds on an August 2021 study of 6-month data from 55 men (average age 58.6) who were randomly assigned to control (n=25) or treatment with PTT (n=30) after prostatectomy. The interventions began 1 month post-surgery, and those in the PTT...

Continuous-Release Anti-VEGF Device for AMD Wins FDA Approval
https://www.medpagetoday.com/ophthalmology/generalophthalmology/95225

Oct 23rd, 2021 - The FDA has approved a first-of-its kind continuous delivery system for anti-VEGF therapy for neovascular (wet) age-related macular degeneration (AMD). The Susvimo ocular implant continuously releases 100 mg/mL of ranibizumab directly to the retina over 6 months. Initial implantation and refill can be performed during an office visit with an ophthalmologist. In contrast, conventional intravitre...

Agenus Withdraws BLA for Balstilimab in Metastatic Cervical Cancer
https://www.onclive.com/view/agenus-withdraws-bla-for-balstilimab-in-metastatic-cervical-cancer

Oct 22nd, 2021 - The immuno-oncology company Agenus has made the decision to withdraw its biologic license application (BLA) for the use of the PD-1 inhibitor balstilimab in patients with recurrent or metastatic cervical cancer who experienced disease progression on, or after, chemotherapy.1 The decision follows the full approval of pembrolizumab (Keytruda) on October 13, 2021, for use as a single agent in pat...

Children With Cancer At Higher Risk for Severe Illness from COVID-19
https://www.onclive.com/view/children-with-cancer-at-higher-risk-for-severe-illness-from-covid-19

Oct 22nd, 2021 - Approximately 20% of pediatric patients with cancer infected with COVID-19 experienced severe illness, according to data published in The Lancet Oncology. Furthermore, deaths due to the infection were proportionally higher in this patient population compared with the general pediatric population, providing evidence that children with cancer are at higher risk of developing severe illness from C...

Oncopeptides Withdraws Melphalan Flufenamide Myeloma Indication in the United States
https://www.onclive.com/view/oncopeptides-withdraws-melphalan-flufenamide-myeloma-indication-in-the-united-states

Oct 22nd, 2021 - Oncopeptides AB (publ) has made the decision to withdraw the indication of melphalan flufenamide (Pepaxto; melflufen) in combination with dexamethasone in select adult patients with relapsed or refractory multiple myeloma from the US market.1 In February 2021, the FDA approved melflufen plus dexamethasone for use in adult patients with relapsed/refractory multiple myeloma who have received at ...

Dr. Burns on the Promise of Combination Regimens in EGFR Exon 20 Insertion+ and KRAS+ NSCLC
https://www.onclive.com/view/dr-burns-on-the-promise-of-combination-regimens-in-egfr-exon-20-insertion-and-kras-nsclc

Oct 22nd, 2021 - Timothy F. Burns, MD, PhD, medical oncologist, UPMC Hillman Cancer Center, associate professor of medicine, associate program director, Research, Hematology/Oncology Fellowship Program, University of Pittsburgh, discusses the promise of combination regimens for patients with EGFR exon 20 insertion– and KRAS G12C–mutated non–small cell lung cancer (NSCLC). Although the approvals of targeted...

Low androgen in kidney recipients tied to diabetes
https://www.mdedge.com/endocrinology/article/247792/diabetes/low-androgen-kidney-recipients-tied-diabetes
Miriam E. Tucker

Oct 22nd, 2021 - Low androgen levels appear to be linked to the development of posttransplantation diabetes mellitus (PTDM) in male kidney transplant recipients, new research suggests. London_England/Thinkstock Among 243 men who did not have diabetes prior to undergoing kidney transplantation, levels of both dihydrotestosterone (DHT) and testosterone were inversely related to the risk for developing diabetes th.

Exercise may help stall MS disability and progression
https://www.mdedge.com/neurology/article/247787/multiple-sclerosis/exercise-may-help-stall-ms-disability-and-progression
Jim Kling

Oct 22nd, 2021 - Though once regarded with suspicion, exercise as a therapy for multiple sclerosis (MS) has gained traction in recent years, and has the potential to counter the physical effects often seen among patients, as well as reduce risk of progression. Dr.

TAS-102 Plus Bevacizumab Misses PFS End Point in Frontline Unresectable Metastatic CRC
https://www.onclive.com/view/tas-102-plus-bevacizumab-misses-pfs-end-point-in-frontline-unresectable-metastatic-crc

Oct 22nd, 2021 - The frontline combination of trifluridine/tipiracil (TAS-102; Lonsurf) and bevacizumab (Avastin) was not found to result in a significant improvement in progression-free survival (PFS) over capecitabine and bevacizumab in patients with unresectable metastatic colorectal cancer (mCRC) who are not eligible to receive intensive therapy, missing the primary end point of the phase 3 SOLSTICE trial (...

Myeloma Drug Pulled From Market Just Months After Approval
https://www.medpagetoday.com/hematologyoncology/myeloma/95223

Oct 22nd, 2021 - Just months after FDA granted accelerated approval of its myeloma drug, Oncopeptides has pulled melphalan flufenamide (melflufen, Pepaxto) from the market. The decision followed an FDA hold on clinical trials of the drug after data from a confirmatory trial showed an increased mortality risk in patients treated with melflufen. The phase III OCEAN study compared melflufen plus dexamethasone and ...

A Wealth of Therapeutic Advances in Lung Cancer Stress a Need for Early NGS Testing
https://www.onclive.com/view/a-wealth-of-therapeutic-advances-in-lung-cancer-stress-a-need-for-early-ngs-testing

Oct 22nd, 2021 - The overwhelming number of options for the treatment of patients with lung cancer underscores the importance of broad molecular testing up front to ensure patients receive optimal care, said Stephen V. Liu, MD. Our strategies [for managing lung cancer] are becoming more sophisticated and precise, but the first step of broad next-generation sequencing [NGS] is really the key. NGS is essential t...

FDA Approves Companion Diagnostic for Adjuvant Atezolizumab in Stage II to IIIA NSCLC
https://www.onclive.com/view/fda-approves-companion-diagnostic-for-adjuvant-atezolizumab-in-stage-ii-to-iiia-nsclc

Oct 22nd, 2021 - The FDA has approved the VENTANA PD-L1 (SP263) assay to assist in identifying which adult patients with stage II to IIIA non–small cell lung cancer (NSCLC) whose tumors have PD-L1 expression on 1% or more of tumor cells are eligible to receive adjuvant atezolizumab (Tecentriq) following surgery and platinum-based chemotherapy.1 Adjuvant atezolizumab was approved for use in this indication on O...

Too Many TAVR Centers Are Clustered Around Well-to-Do Communities
https://www.medpagetoday.com/cardiology/pci/95213

Oct 22nd, 2021 - The proliferation of transcatheter aortic valve replacement (TAVR) programs in the U.S. was largely limited to metropolitan areas and hospitals serving relatively affluent patients, a study found. Only 2% of the 583 hospitals with a TAVR program by the end of 2018 were not located in metropolitan areas, and there was only one rural center. Furthermore, half of new programs established in 2012 t...

Will Slow and Steady Progress in Treating SCLC Win the Race?
https://www.onclive.com/view/will-slow-and-steady-progress-in-treating-sclc-win-the-race-

Oct 22nd, 2021 - Clinical advances in the treatment of small cell lung cancer (SCLC) have lagged behind those of other tumor types, but the delay is not for lack of effort. In recent years, however, improved understanding of disease biology has identified some novel targets that may make these tumors more vulnerable to treatment. One such approach in the frontline setting has been the integration of various imm...

Many States Frown Upon Medicaid Coverage of Penile Implants for ED
https://www.medpagetoday.com/urology/erectiledysfunction/95204

Oct 22nd, 2021 - SCOTTSDALE, Ariz. -- At least 21 states still don't provide Medicaid coverage for penile implants in patients with erectile dysfunction (ED), a new study found. In contrast, 49 states cover male urethral slings, and 48 states cover insertion of artificial urinary sphincters for male incontinence, reported John Barnard, MD, of West Virginia University in Morgantown, who presented the findings at...

Cabozantinib Shows Activity Against RCC Brain Metastases
https://www.medpagetoday.com/hematologyoncology/renalcellcarcinoma/95201

Oct 22nd, 2021 - The tyrosine kinase inhibitor (TKI) cabozantinib (Cabometyx) showed promising activity against brain metastases from renal cell carcinoma (RCC), researchers reported. In a retrospective cohort study of 88 patients with RCC brain metastases, the intracranial response rate with cabozantinib was 55% (95% CI 36-73%) in those with progressing brain metastases without concomitant brain-directed local...

Institutional Perspectives in Cancer Webinar- Lung: Chaired by Edward B. Garon, MD
https://www.onclive.com/view/institutional-perspectives-in-cancer-webinar--lung-chaired-by-edward-b-garon-md

Oct 21st, 2021 - Institutional Perspectives in Cancer- Lung: Chaired by Edward B. Garon, MD The live filming of this virtual event in our IPC series is now on-demand. OncLive is proud to present the State of the Science Summits and a new virtual event, Institutional Perspectives in Cancer (IPC). Each summit and webinar will convene for a short meeting designed to educate healthcare professionals on the clin...

Institutional Perspectives in Cancer- Breast: Chaired by Paul L. Baron, MD
https://www.onclive.com/view/institutional-perspectives-in-cancer--breast-chaired-by-paul-l-baron-md

Oct 21st, 2021 - The live filming of this virtual event in our IPC series is now on-demand. OncLive is proud to present the State of the Science Summits and a new virtual event, Institutional Perspectives in Cancer (IPC). Each summit and webinar will convene for a short meeting designed to educate healthcare professionals on the clinical benefits associated with new science driving new thinking in cancer manag...

Dr. Hansen on the Utilization of BCMA-Directed Therapy in Multiple Myeloma
https://www.onclive.com/view/dr-hansen-on-the-utilization-of-bcma-directed-therapy-in-multiple-myeloma

Oct 21st, 2021 - Doris Hansen, MD, assistant member, Moffitt Cancer Center department of blood and marrow transplant and cellular immunotherapy, discusses the utilization of BCMA-directed therapy in multiple myeloma. his is an exciting time for the treatment of patients with multiple myeloma, as several agents have been approved in the past few years, Hansen says. However, patients have passive responses with ...

EC-18 Reduces Duration and Incidence of Chemoradiation-Induced Oral Mucositis in Head and Neck Cancer
https://www.onclive.com/view/ec-18-reduces-duration-and-incidence-of-chemoradiation-induced-oral-mucositis-in-head-and-neck-cancer

Oct 21st, 2021 - Treatment with the small molecule oral immunomodulator EC-18 resulted in a reduction in both the duration and incidence of severe oral mucositis (SOM) in patients with head and neck cancer who are undergoing concurrent chemoradiation, meeting both primary and secondary end points of the phase 2 CRIOM study (NCT03200340).1 With a short-term follow-up period, EC-18 reduced the duration of SOM fr...